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Abstract
Oral cancer is the eighth most common cancer worldwide and represents a significant disease burden. If detected
at an early stage, survival from oral cancer is better than 90% at 5 years, whereas late stage disease survival is only
30%. Therefore, there is an obvious clinical utility for novel metabolic markers that help to diagnose oral cancer at
an early stage and to monitor treatment response. In the current study, blood samples of oral cancer patients were
analyzed using nuclear magnetic resonance spectroscopy to derive a metabolic signature for oral cancer. Using
multivariate chemometric analysis, we obtained an excellent discrimination between serum samples from cancer
patients and from a control group and could also discriminate between different stages of disease. The metabolic
profile obtained for oral cancer is significant, even for early stage disease and relatively small tumors. This suggests
a systemic metabolic response to cancer, which bears great potential for early diagnosis.
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Introduction
Oral squamous cell carcinoma (OSCC) is the eighth most common
cancer worldwide and represents a well-defined subgroup of head and
neck cancer [1,2]. It has a 5-year mortality of 45% to 60% dependent
on the setting and patient group, and the disease is frequently associated
with tobacco smoking and excessive alcohol intake [3,4]. The main
treatment of OSCC is radical surgery. High-stage disease frequently re-
quires postoperative adjuvant radiotherapy to “mop-up” residual disease
and is therefore more distressing for patients and, unfortunately, less
successful in survival when compared with treatment of low-stage dis-
ease. Whereas patients with high-stage tumors of larger size and higher
metastatic potential have only a 30% chance of survival at 5 years, pa-
tients with low-stage cancer have an 80% to 90% chance of survival.
A high degree of clinical skill is required to detect OSCC, and this
is not widely available. The development of detection methods (such
as blood tests) that can act as a surrogate for a highly skilled clinical
examination would allow detection of OSCC at an early stage as well
as monitoring response to treatment and helping to identify residual
disease after treatment. This would significantly improve survival as
treatment of early stage disease has been shown to be more successful.
Nuclear magnetic resonance (NMR) spectroscopy is a commonly
used analytical method to analyze the small molecule composition,
that is, the metabolome, of body fluids such as urine and blood serum.
Variations in metabolite concentrations have been associated with the
biochemical status of organisms and reflect changes in metabolism
arising from biologic conditions, including disease and response to
chemical treatment. Recent studies demonstrate the applicability of
NMR-based metabolomics using serum samples for the diagnosis
and prognosis of disease [5–13].
Both 1H and 31P magnetic resonance spectroscopy have previously
been used to identify metabolic signatures of squamous cell carcinoma
compared with benign tumors and normal tissues [14–21]. Both
in vivo and in vitro clinical studies have shown that the choline-
creatine ratio is significantly higher in OSCC than in normal tissue
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[18–20]. Analysis of squamous cell carcinoma cell line cultures was
suggestive of rapid membrane biosynthesis due to increased cell pro-
liferation [19]. Moreover, in vitro studies using two-dimensional
(2D) correlated spectroscopy revealed that a variety of metabolites,
such as alanine, glutathione, histamine, isoleucine, and leucine, were
found at a higher concentration in tumor tissue compared with the
normal tissue [19]. An NMR study of ex vivo tumor tissue found
elevated concentrations of taurine, choline, glutamic acid, lactic acid,
and lipids in squamous cell tissue compared with normal tissue [17].
Many solid tumors show an increased glycolytic metabolism,
which has, in the case of OSCC, been associated with the overexpres-
sion of glucose transporters especially of Glut-1 [22]. This change in
metabolism is commonly used to locate primary tumors and associ-
ated metastases using positron emission tomography by monitoring
[18F]-2-fluoro-2-deoxy-D-glucose uptake [22]. Other authors have
examined the role of advanced glycated end products (AGE) and in-
creased levels of the AGE receptor (RAGE) in patients with diabetes
mellitus type 2 and primary gingival carcinoma showing that RAGE
expression is closely associated with the invasiveness of OSCC [23,24].
Here, we present a pilot study analyzing serum samples of a small
number of patients with OSCC and normal control individuals to
identify characteristic changes to metabolite profiles in patients with
OSCC. This allowed us to probe the highly relevant question of
whether early stage tumors with a size of <2 cm and therefore
<0.005% of bodymass can be detected using a metabolomics approach.
Materials and Methods
Patient Characteristics and Sample Collection
After ethical committee approval and written patient consent,
samples of venous blood were collected from sequential patients with
histologically confirmed OSCC at the University Hospital Birming-
ham NHS Foundation Trust, Birmingham, United Kingdom. Con-
trol samples were taken from normal donors who had no personal
history of cancer. All samples were taken at around the same time
during the day for each patient.
Samples were harvested by standard venepuncture, and 10 ml of
blood was acquired and immediately transferred to a sterile universal
container without anticoagulant. This was centrifuged at 3500 rpm
for 5 minutes. The supernatant was removed in 1-ml aliquots, and
samples were immediately quenched in liquid nitrogen until serum
was frozen and later transferred to a −80°C freezer for storage.
Samples were harvested from 15 cancer patients: 5 males and 10
females of average age of 63.8 years. Patient characteristics, staging of
disease, and other parameters are shown in Table 1. The UK average
age for patients with oral cancer is 63.5 years, which is well repre-
sented by this study. There is an unexpectedly high proportion of
females in this cohort; the national average is a ratio of 2:1 in favor
of males. No significance is attached to the high proportion of fe-
males in the study population because the patients were taken from
sequentially presenting patients in a single unit.
Ten blood samples were harvested from normal healthy donors: six
males and four females of average age of 57 years (Table 1). Tumors
were staged according to standard American Joint Committee on
Cancer classification for head and neck and oral cancer [25].
Sample Preparation
Approximately 0.5 ml of human serum was filtered (Nanosep 3K
OMEGA; Pall Corporation, Ann Arbor, MI) at 4°C using a centrifuge
at 10,000 rpm [26]. Three hundred twenty microliters of filtered serum
was diluted adding 90 μl of distilled water. One hundred forty micro-
liters of phosphate buffer 0.4 M containing 0.75% w/v sodium azide
and 50 μl of 3.25 mM 3-(trimethylsilyl)propionate-2,2,3,3-d4 (TMSP;
Cambridge Isotope Laboratories) in D2O (99.9% pure; GOSS Scien-
tific Instruments Ltd, Essex, UK) were added to the filtered serum. The
final pH of the solution was adjusted to 7.0 (± 0.1). The sample trans-
ferred to the NMR tube contained 600 μl of filtered serum.
Nuclear Magnetic Resonance Data Acquisition
One-dimensional (1D) 1H and 2D 1H J -resolved (JRES) NMR
spectra [27] were acquired using a 500-MHz Bruker spectrometer
(Bruker Biospin, Rheinstetten, Germany) equipped with a cryogeni-
cally cooled probe at 303.15 K. Proton spectra were referenced to
the TMSP signal (δ 0.00 ppm). In both pulse sequences, the water
resonance was suppressed using excitation sculpting [28]. One-
dimensional spectra were acquired using a 60° flip angle, a 5-kHz
spectral width, and a relaxation delay of 3 seconds; 128 transients were
collected with 16,384 data points and eight dummy scans. Two-
dimensional JRES spectra were collected using a double spin-echo
sequence with 16 transients per increment at 32 increments. Strong cou-
pling artifacts were suppressed by phase cycling [29]. Two-dimensional
COSY experiments were carried out using an 800-MHz Varian spec-
trometer (Varian, Palo Alto, CA) equipped with a cryogenically cooled
probe using a gradient-selected coherence transfer pathway (gCOSY45
[30]) with 16 transients of 8192 complex data points, 256 increments,
and a spectral width of 8 kHz in both dimensions.
Nuclear Magnetic Resonance Data Processing
and Postprocessing
Nuclear magnetic resonance data were processed using NMRLab
[31] and MetaboLab (U. Günther, unpublished software) in the
Table 1. Age, Sex, Disease Stage, and Weight Changes of OSCC Patients.
Sample Age Sex Stage Weight (kg) Weight Change (kg)
Cancer patients
B01 71 F IV 63 −6
B02 46 M I 100
B03 66 F II 35 −25
B04 66 F I 81
B05 56 F II 70
B06 49 F IV 47 −20
B07 84 M IV 63
B08 72 M III 68 −10
B09 69 F IV 85
B10 63 F II 82
B11 61 F I 69
B12 52 M IV 62
B13 75 F II 74
B14 60 M II 65
B15 67 F III 79
Normal controls
C01 40 F
C02 46 M
C03 49 M
C04 55 F
C05 56 M
C06 57 M
C07 60 M
C08 62 F
C09 72 F
C10 77 M
Weight change, before surgical intervention.
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MATLAB (TheMathWorks, Inc., Natick, MA) programming environ-
ment. Postprocessing included scaling, alignment, exclusion of water
and TMSP signals, binning at 0.005 ppm, and application of a gener-
alized log transformation [32] to enhance small signals in the spectrum.
Before Fourier transformation, 2D JRES were multiplied by a com-
bined sine-bell/exponential window function in the direct dimension
and by a sine bell function in the incremented dimension [33]. The
spectra were processed and tilted in frequency space by 45°; projections
were calculated after tilting and symmetrizing using NMRLab [31] to
simplify 1D spectra and to reduce peak congestion. Alternatively, we
also recovered coupled 1D spectra by omitting the 45° rotation for
metabolite identification using the Chenomx NMR Suite software
(version 5; Chenomx Inc., Edmonton, Canada).
Statistical Analysis
Unsupervised (principal component analysis, PCA) and supervised
(PLS-DA) multivariate analyses in PLS-Toolbox (Version 4.1; Eigen-
vector Research, Manson, WA) were used for statistical data analysis.
Cross-validation applying the “Venetian blind” algorithm has been used
for all PLS-DA analyses. Metabolites were identified from loadings plots
using the Chenomx NMR Suite software (version 5; Chenomx Inc.).
Results
Figure 1 depicts the superimposition of two representative 1H NMR
spectra (projections of JRES spectra), which show the average signals
from healthy (blue line) and diseased (red line) subjects. The spectra
are dominated by the resonances of carbohydrates, in particular, both
anomeric forms of glucose (∼3-5.5 ppm, Gluc) and some of the inter-
mediate metabolites of the glycolytic pathway, such as lactate (δ 1.33
and 4.11 ppm, Lac). Other compounds such as amino acids, in particu-
lar, valine (Val, 0.9-1.1 ppm) and alanines (Ala, 1.46 ppm), show large
methyl signals in the spectrum. Smaller contributions to the spectrum
are often more relevant to the analysis and are enhanced by applying
a generalized log transformation (Figure 1) [32].
One-dimensional and 2D JRES NMR spectra were recorded for
filtered blood sera from patients with head and neck cancers and
from a control group of healthy volunteers. Two-dimensional JRES
spectra were used to visualize both chemical shifts and scalar cou-
plings along different spectral dimensions and increase peak disper-
sion and therefore metabolite specificity in 1D projections [34].
Principal component analysis applied to 1D projections is depicted
in Figure 2 and shows a clear separation between samples from
healthy subjects and OSCC patients. Samples from patients with
the disease group geared toward smaller or negative values of PC2;
samples from higher stage disease also spread out toward higher posi-
tive values of PC1. Furthermore, the PCA result shows clustering
according to the stage of disease; samples B06, B07, B08, B09, and
B12 are from patients with stages III and IV disease, with associated
metastasis, and are observed at higher absolute values of PC1 and
PC2. Samples B01 and B15 represent an exception to good separation
of low- and high-stage disease, which, in the case of B01, can be attrib-
uted to the small size of the tumor that was classified as high-stage IV
because it had invaded the locally adjacent bony structures although
there was no indication of metastatic disease. Therefore, PCA not only
differentiates disease and control samples but also shows significant
potential to distinguish early and late stage disease with high specificity.
Figure 1. Superimposition of two representative 1H NMR spectra (projections of JRES spectra), which show the average signals from
the serum samples of healthy subjects (blue line) and patients with disease (red line) after application of a generalized log transforma-
tion. Predominant metabolite resonances are labeled on the spectrum. Ala indicates alanine; Gluc, glucose; Lac, lactate; Val, valine.
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To obtain a more objective statistical estimation and specific load-
ings, we used PLS-DA for a model discriminating samples from cancer
patients and controls (Figure 3). In this case, the sensitivity and speci-
ficity for oral cancer detection are both >95% (see receiver operating
characteristic curves in Figure W1) after applying the Venetian blind
algorithm for cross-validation. Despite limited statistical significance
owing to a small number of samples, this result is remarkable consid-
ering that some early stage tumors were below 0.005% of the overall
body mass.
To probe for a possible bias arising from other factors, we probed
the ensemble of data for the influence of age and sex. Both factors do
not cluster in the unsupervised PCA. Therefore, PLS-DA analyses
were used to build models for disease, age, and sex. In this analysis,
a substantially less-pronounced clustering and a lower degree of
specificity and sensitivity were observed for age and sex compared
with disease versus control (see receiver operating characteristic curves
in Figures W1–W3).
Loadings plots were calculated from PLS-DA models to identify
discriminatory metabolites for different models. Figure 4, A and B,
shows different areas of loadings in the first latent variable of PLS-DA,
with positive values representing healthy controls and negative values
representing patients with disease. In the samples from cancer patients,
the levels of valine, ethanol, lactate, alanine, acetate, citrate, phenylala-
nine, tyrosine, methanol, formaldehyde, and formic acid were reduced
compared with those of healthy controls, whereas signals arising from
glucose, pyruvate, acetone, acetoacetate, 3-hydroxybutyrate and 2-
hydroxybutyrate, choline, betaine, and, to a lesser degree, dimethylgly-
cine, sarcosine, asparagine, and ornithine showed enhanced loadings.
In the aromatic region, additional contributions arise from yet uniden-
tified metabolites. These contributions were summarized in metabolic
pathways shown in Figure 5. To avoid possible errors arising from
PLS-DA for a small sample size, we compared these results with differ-
ences of average late and early stage spectra, which gave the same results.
To identify the metabolites that are responsible for the distinction
between different stages of disease, PLS-DAmodels using only samples
from patients with disease were built (not shown). Loadings plots from
latent variable 1 are displayed in Figure 6, A and B, showing similar
patterns as for the distinction between patients with disease and
healthy controls (Figure 4, A and B). In samples from patients with
late stage disease, the levels of 2-hydroxybutyrate, 3-hydroxybutyrate,
acetone, acetate, acetoacetate, creatinine, asparagine, glucose, dimethyl-
glycine, betaine, and choline were remarkably increased compared with
patients with early stage disease, whereas valine, lactate, alanine, pyru-
vate, lysine, creatine, acetyl-L-carnitine, and carnitine showed reduced
concentrations (Figure 6, A and B). In addition, a model using three
classes (healthy controls and patients with early and late stage diseases)
is shown in Figure W4. The application of this multivariate chemo-
metricmodel shows a clear separation between the samples from healthy
controls and patients with disease. Very narrow groupings are observed
for the control samples and the patients with early stage disease. On the
contrary, the sera of patients with late stage disease are more widely
spread in the scores plot highlighting the higher inhomogeneity of their
metabolic profile.
Discussion
This study shows an unexpectedly strong metabolic profile in
blood sera of patients with OSCC with a significant signature even
for low-stage tumors. Subsequent analysis of metabolite profiles of
serum samples from oral cancer patients can distinguish patients with
disease from healthy normal controls and can also discriminate pa-
tients with high- and low-stage diseases and provide a fingerprint
of metabolic changes. Although the statistical relevance of this study
Figure 2. Principal components analysis scores plot of 1H NMR spectra of human blood sera from OSCC patients (•) and from healthy
controls (▾).
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is limited by the small number of samples, a strong signature was
obtained using an unbiased and unsupervised PCA. This is an aston-
ishing result considering the relatively small size of the tumors (less
than 0.005% of total body mass for early stages) and the fact that
some patients (B02, B03, B04, B05, B10, B11, B13, and B14)
had localized tumors without metastasis or only small locoregional
metastasis. Sensitivity and specificity were both remarkably high
for the detection of disease. Discrimination between disease stages
in PCA was also remarkable with only two samples from patients
with stages IV and III disease (B01 and B15) clustering with low-stage
Figure 3. PLS-DA scores plot of 1HNMR spectra of human blood sera using two classes: OSCCpatients (•early and▪ late stage diseases)
and healthy controls (▾).
Figure 4. Loadings plots for the first principal component for different regions of the spectrum. A representative NMR spectrum of human
serum from an OSCC patient is shown above the loadings plots. Signals representing the most relevant discriminatory metabolites of
healthy individuals (positive loadings) and OSCC patients (negative loadings) are labeled (A and B). 2HB indicates 2-hydroxybutyrate;
3HB, 3-hydroxybutyrate; Ac, acetone; Ace, acetate; AceAce, acetoacetate; ACL, acetyl-L-carnitine; Ala, alanine; Asn, asparagine; Bet,
betaine; Car, carnitine; Cho, choline; Cit, citrate; Cr, creatine; Cre, creatinine; DMG, dimethylglycine; EtOH, ethanol; Gln, glutamine; Gluc, glu-
cose; Gly, glycine; Lac, lactate; Lys, lysine;MeOH,methanol; Orn, ornithine; Pro, proline; Pyr, pyruvate; Sar, sarcosine; Ser, serine; Val, valine.
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samples. For B01, this has been attributed to the fact that the tumor
was small but had invaded the locally adjacent bony structures, al-
though there was no indication of metastatic disease. Based solely on
size and in absence of the bony invasion, this tumor would have been
classified as stage I or II. Many believe such upstaging to be incorrect,
and certainly, this tumor was biologically more similar to low-stage dis-
ease and may explain why it clustered with the other low-stage tumors.
Because blood serum represents the effects of metabolism in differ-
ent organs, it is difficult to assign a metabolic fingerprint to specific
metabolic processes. Nevertheless, changes in blood serum metabolite
Figure 6. Loadings plots (latent variables) from a PLS-DA analysis of OSCC patients showing metabolites that discriminate between
early (positive loadings) and late stage diseases (negative loadings). A representative NMR spectrum of human serum from an OSCC
patient is shown above the loadings plots.
Figure 5. Schematic representation of the most relevant metabolic differences between oral cancer patients and healthy controls.
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concentrations of patients with OSCC clearly point to an altered en-
ergy metabolism. The relatively high level of glucose and low level of
lactate is strikingly different to observations in other types of cancer
where, commonly, lactate levels are high [10,35]. It is unlikely that
the high level of glucose can be ascribed to any other disorder because
none of the patients was diagnosed with any other medical condition
leading to elevated glucose. It is possible that the levels of glucose may
be linked to the unique behavior of oral cancer, which interferes with
the ability of insulin to modulate the uptake of glucose and thus regu-
lates consequent energy metabolism favoring the accumulation of car-
bohydrates and the process of ketogenesis [36–39]. Several potential
precursors of glucose in gluconeogenesis, such as lactate, alanine, and
other gluconeogenic amino acids [40–42], were found at lower concen-
trations in patients with head and neck cancer. This clearly points to an
altered energy metabolism, although it is not possible to assign changes
to specific pathways considering that blood samples represent a cross-
section of metabolic events in multiple organs.
The increased level of ketone bodies can be linked to lipolysis as
a backup mechanism for energy production. This signature cannot
be a consequence of fasting because all patients with OSCC received
optimal nutrition according to a standard protocol of calorific re-
quirement. Enteral tube feeding was used if patients were unable
to swallow. Moreover, of the 15 patients, only 2 had lost significant
amounts of weight (B03 and B06) and 2 others showed moderate
weight loss (B01 and B08). Importantly, samples from these patients
were grouped according to the disease stage with the already dis-
cussed exception of B01. This shows that the cancer signature domi-
nates in these samples.
Furthermore, several Krebs cycle intermediates such as citrate, suc-
cinate, and formate were less concentrated in patients with disease
suggesting a suppressed Krebs cycle. This represents a typical signa-
ture in cancer patients, and it has been previously associated with the
“Warburg effect” [43], which assumes that tumors rely on glycolysis
as a main source of energy, even in the presence of oxygen.
Elevated levels of 2-hydroxybutyrate may be associated with protein
and amino acid catabolism. This is also supported by vastly altered
amino acid profiles of head and neck cancer patients. For example, or-
nithine and asparagine levels were higher in oral cancer patients than in
control samples. This result is in agreement with previous observations
where blood plasma free amino acid pattern profiles were diagnostically
correlated with the organ site for three different types of malignant tu-
mors [44]. Ornithine represents a metabolite found in the urea cycle,
which can use amino acid breakdown products to feed into the Krebs
cycle. Besides ornithine, the blood levels of most essential and non-
essential amino acids (such as threonine, valine, isoleucine, leucine, gly-
cine, tyrosine, and phenylalanine) were found to be lower in the cancer
patients. A significant decrease in blood plasma threonine and glycine
has previously been reported at the early stage of head and neck cancer
[44,45] but has been attributed to dysphagia and consequent insuffi-
cient food intake rather than to the disease itself. However, this is an
unlikely cause in the present study because optimal nutrition was en-
sured for all patients.
In agreement with previous reports analyzing OSCC tumor sam-
ples [16,18,19], serum samples showed creatine to be low, creatinine
to be high, and choline-creatine ratios to be high. Choline and its
derivatives represent important constituents in phospholipid metabo-
lism of cell membranes [46] and have been previously identified as
markers of cellular proliferation. In the context of the metabolite pro-
file associated with OSCC in this study, choline, together with beta-
ine, dimethylglycine, carnitine, and acetyl carnitine, allows a distinct
differentiation between early and late stage diseases.
In summary, patients with OSCC show a distinct signature of
altered energy metabolism in blood serum, which includes altered
lipolysis (an accumulation of ketone bodies), a distorted Krebs cycle,
and amino acid catabolism. Most of the observed effects are more
pronounced in late stage OSCC, and some metabolites show specific
changes in the later stages of disease. Such measurements might revo-
lutionize cancer treatment if early stage disease can be detected equally
well in other cancers and if the obtained signatures show specificity for
the individual type of disease.
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Figure W1. Receiver operating characteristic curves of sensitivity versus specificity (the plots on the left) and threshold versus specificity/
sensitivity (the plots on the right) calculated for cross-validated PLS-DA applied to NMR spectra of serum samples from healthy controls
(class 1) and patients affected by oral cancer (class 2). A high degree of specificity and sensitivity is observed.
Figure W2. Receiver operating characteristic curves of sensitivity versus specificity (the plots on the left) and threshold versus specificity/
sensitivity (the plots on the right) calculated for cross-validated PLS-DA applied to NMR spectra from healthy controls below (class 1) and
above (class 2) the mean age. Compared with Figure W1, a lower degree of specificity and sensitivity is observed.
Figure W3. Receiver operating characteristic curves of sensitivity versus specificity (the plots on the left) and threshold versus specificity/
sensitivity (the plots on the right) calculated for PLS-DA applied to NMR spectra with groups for sex (male: class 1 and female: class 2).
Compared with Figure W1, a lower degree of specificity and sensitivity is observed.
Figure W4. PLS-DA scores plot of 1H NMR spectra of human blood sera using three different classes for patients with•early and ▪ late
stage diseases and healthy controls (▾). The application of this multivariate chemometric model shows a clear separation between the
samples from healthy controls and the patients with disease. Very narrow groupings are observed for the control samples and the
patients with early stage disease. On the contrary, the sera of patients with late stage disease are more widely spread in the scores
plot, highlighting the higher inhomogeneity of their metabolic profile.
